In vitro metabolism of a novel PPARγ agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s

References

• Agranat I, Caner H, Caldwell J. Putting chirality to work: The strategy of chiral switches. Nature Reviews in Drug Discovery 2002; 1: 753–768
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 2001; 40: 411–426
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261–270
   PubMed Web of Science ®Google Scholar
• Berger JP, Petro AE, MacNaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Molecular Endocrinology 2003; 17: 662–676
   PubMed Web of Science ®Google Scholar
• Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1996; 277: 321–332
   PubMed Web of Science ®Google Scholar
• Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology 1989; 28: 29–36
   PubMed Web of Science ®Google Scholar
• Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discovery Today 2004; 9: 105–110
   PubMed Web of Science ®Google Scholar
• Gross AS, Eichelbaum M, Morike K, Mikus G. Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. British Journal of Clinical Pharmacology 2000; 49: 132–138
   PubMedGoogle Scholar
• Kim JY, Baek M, Lee S, Kim SO, Dong MS, Kim BR, Kim DH. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2001; 29: 1555–1560
   PubMed Web of Science ®Google Scholar
• Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2003; 31: 1227–1234
   PubMed Web of Science ®Google Scholar
• Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG. KR-62980: A novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Biochemical Pharmacology 2006; 72: 446–454
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2005; 19: 2651–2658
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 2002; 30: 1108–1114
   PubMed Web of Science ®Google Scholar
• Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, Gershome C, Rajjak A, Kashireddy P, Yu S, et al. PAT5A: A partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 763–771
   PubMed Web of Science ®Google Scholar
• Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proceedings of the National Academy of Sciences of the USA 1999; 96: 6102–6106
   Google Scholar
• Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular Cell 2001; 8: 737–747
   PubMed Web of Science ®Google Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino JS, Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216
   PubMedGoogle Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272
   PubMed Web of Science ®Google Scholar
• Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 2001; 50: 411–417
   PubMed Web of Science ®Google Scholar